News

For additional information
on JADO contact us at:
info@jado-tech.com

09/16/2009

JADO’s Broad European Patent on Use of Tripartite Compounds Granted

03/10/2009

JADO Awarded EUR1.9 Million Grant to Develop New Allergic Disease Treatments

01/15/2009

JADO Technologies Announces Departure of CEO

12/17/2008

JADO Granted European Patent Covering Use of Sphingolipid Derivative to Target Raft Pathological Processes

11/11/2008

JADO Secures EUR 3.9 Million in Series B Financing

10/06/2008

JADO Opens In-Silico Department in the University of Bonn

07/02/2008

JADO Initiates Phase II Trials of Lead Raft Modulator in Urticaria

04/24/2008

Novel Approach to Treat Alzheimer’s and other Diseases Offered by Targeting Cell Membrane Rafts

02/18/2008

JADO Reports Clinical Proof of Concept with Raft Modulator in Atopic Dermatitis

10/10/2007

JADO Technologies Licenses Clinical Data from Æterna Zentaris for Use of Miltefosine in Allergy Indications

09/04/2007

JADO Technologies Appoints New Chief Executive Officer

05/02/2007

JADO Technologies Initiates Clinical Phase IIa in Cutaneous Mastocytosis with First-in-Class Allergy Therapeutic

01/15/2007

Saxon Order of Merit Awarded to JADO Technologies Founder, Prof. Kai Simons

12/11/2006

JADO Opens New BSL3 Level Research Labs in Potsdam for Drug Development on HIV/AIDS and Bird Flu

12/05/2006

JADO Technologies Founder – Prof. Hans-Joachim Knölker – Honoured with a Fellow of the Royal Society of Chemistry

08/30/2006

JADO Technologies Raises €3 Million to Begin Clinical Trials

04/13/2006

JADO Technologies Founder – Prof. Hans-Joachim Knölker – Elected to the Saxon Academy of Sciences

12/02/2005

JADO Technologies Founder – Prof. Marino Zerial – Awarded the Prestigious 2006 Leibniz Prize